M13 bacteriophage-based vaccine design for prion.
Project/Area Number |
22790435
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
Virology
|
Research Institution | Kagoshima University |
Principal Investigator |
|
Project Period (FY) |
2010 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | バクテリオファージ / ワクチン / 自然免疫 / プリオン / 抗体 / ファージディスプレイ / 免疫 |
Research Abstract |
Phage display library is powerful tool to develop various recombinant peptides or human antibodies applicable for revolutionary therapeutics. In addition to this feature, peptide-displaying phage clones induce mimotope-specific antibody responses in mice. In this study, we have established a human IgG1 antibody specific to s-form prion protein(PrP) but not to.-form PrP, PRB7 IgG. Employing a peptide-displaying phage library, the mimotope was determined to be at# 128-132 of human PrP. A single injection of peptide-displaying phage stimulate innate immune response and elicited a strong IgG response in mice, suggests a possible application of peptide-displaying phage clones as vaccine carriers for induction of therapeutic antibodies.
|
Report
(3 results)
Research Products
(25 results)
-
[Journal Article] Direct evidence of generation and accumulation of β-sheet-rich prion protein in ScN2a cells de novo illuminated by human IgG1 antibody recognizing β-form but not α-form of prion protein2012
Author(s)
Toshiya Kubota, Yuta Hamazoe, Shuhei Hashiguchi, Daisuke Ishibashi, Kazuyuki Akasaka, Noriyuki Nishida, Shigeru Katamine, Suehiro Sakaguchi, Ryota Kuroki, Toshihiro Nakashima, Kazuhisa Sugimura.
-
Journal Title
The Journal of biological chemistry
Volume: 287巻
Issue: 17
Pages: 14023-14039
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-